Feasibility and Safety of an 8 F Angioseal® Vascular Closure Device for Closure of Large Bore Impella CP® Access. (June 2022)

• Record Type: Journal Article
• Authors: Zachoval, Christian F.; Sedaghat, Alexander; Oezkur, Mehmet; Tiyerili, Vedat; Becher, Marc U.; Sinning, Jan-Malte; Treede, Hendrik; Nickenig, Georg; Zimmer, Sebastian
• Is Part Of: Journal of endovascular therapy. Volume 29:Number 3(2022)
• Page Start: 336
• Page End: 342
• Publication Date: 2022-06
• Subjects: Impella CP® -- AngioSeal® -- large bore access -- vascular closure device -- percutaneous mechanical circulatory support; Blood-vessels -- Endoscopic surgery -- Periodicals; Angioscopy -- Periodicals; Intravenous catheterization -- Periodicals; Peripheral vascular diseases -- Treatment -- Periodicals; Vascular Surgical Procedures -- Periodicals; Angioscopy -- Periodicals; Catheterization, Peripheral -- Periodicals; Peripheral Vascular Diseases -- therapy -- Periodicals; Angioscopie; Maladies vasculaires périphériques; 617.413
• DOI: 10.1177/15266028211047965
• Languages: English
• ISSNs: 1526-6028

Abstract

Purpose: Percutaneous mechanical circulatory support (pMCS) with the Impella ® device is routinely used in cardiogenic shock and high risk percutaneous coronary interventions (PCI). However, safety and feasibility to close the large bore access (LBA) post-hoc remain a challenge. Materials and Methods: In patients with planned termination of Impella therapy, corresponding LBA closure was attempted using an undersized AngioSeal ® device, which was deployed after insertion of a 0.035 in J-wire through the guidewire access port. Cross-over angiographic visualization before and after deployment as well as in-hospital follow up were performed to assess closure success and screening for short-term adverse events. Results: We evaluated 17 patients (68 year old, IQR 58–76, 71% male) in whom 14 F LBA closure after pMCS using the Impella CP ® was achieved with an undersized AngioSeal ® device. Clinical indication for pMCS was cardiogenic shock in 94% and protected PCI in 6%. Impella CP ® devices were withdrawn after a median of 4 days (IQR 3–6 days). Primary hemostasis was achieved in the majority of patients (14/17; 82%) while single cross-over balloon inflation led to hemostasis in the remaining patients. One patient suffered acute ischemia later in the course of the disease, but this was not directly related to the closure device. In this study, no major bleeding or other device-related adverse events were observed. Conclusion: The 8 F AngioSeal ® vascular closure device has been safely used for removal of the Impella CP ® microaxial pump in most cases of predominantly normal weight patients. This technique may be considered feasible for post-hoc LBA closure in the context of pMCS, especially when preclosure options are not suitable or unavailable.